The Latest Cardiac and Vascular News
Boston Scientific shared the 3-year MAJESTIC DES data online at CardioVascular and Interventional Radiology MAJESTIC 3-Year Data Published for Boston Scientific’s Eluvia DES, by Endovascular Today October 11, 2017—The 3-year results of the MAJESTIC first-in-human study of the Eluvia paclitaxel-eluting vascular stent […]
MARLBOROUGH, Mass., Oct. 2, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Apama Medical Inc., a privately-held company that is developing the Apama Radiofrequency (RF) Balloon Catheter System for the treatment of atrial fibrillation (AF). […]
The Federal court upheld a previous coronary stent win over Dr. David Jang Appeals court upholds Boston Scientific win over stent pioneer Jang BY BRAD PERRIELLO, MassDevice A federal appeals court today upheld a Boston Scientific (NYSE:BSX) win over coronary stent pioneer Dr. David […]
MARLBOROUGH, Mass., Sept. 25, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) has launched the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the HeartLogic Heart Failure Diagnostic to help physicians improve heart failure (HF) management. […]
DALLAS and MARLBOROUGH, Mass., Sept. 19, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the performance of the HeartLogic Heart Failure Diagnostic to predict impending heart failure (HF) decompensation. […]
PENANG, 11 April 2016 – Expanding its manufacturing footprint in the Asia Pacific region, Boston Scientific Corporation (NYSE: BSX) today marked the commencement of construction work on a regional manufacturing hub during a groundbreaking ceremony in Penang. Located at the Batu […]
FREMONT, Calif. and ST. LOUIS, Sept. 11, 2017 /PRNewswire/ — VENITI®, Inc., a leader in the advancement of treatment for deep venous disease, today announced that Boston Scientific will distribute the VICI VENOUS STENT under a limited global distribution agreement. The terms of the agreement […]
Valencia, CA – August 28, 2017 – SetPoint Medical, a clinical-stage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, announced today that it has secured $30 million in Series D equity financing. The Series D financing will provide […]
SAN DIEGO, Aug. 07, 2017 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) will hold a briefing call on Thursday, August 10, 2017 at 4:00 p.m. PDT (which is 9:00 a.m. AEST on Friday, 11 August 2017). […]
SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) announces the expiration of Boston Scientific Corporation’s (“BSC”) exclusive right to negotiate for distribution of REVA’s coronary and peripheral bioresorbable scaffolds. BSC’s right to […]
